Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089101 · ClinicalTrials.gov registry record · Phase 1
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
A Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 17
- Study locations
NCT01089101: Active Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma, sponsored by National Cancer Institute (NCI).
NCT01089101 is a Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 217 participants, above the 104-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (109% higher). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01089101, a Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 17
- Study locations
Study Summary
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Selumetinib
Study Locations (17)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mount Zion - San Francisco
- UCSF Medical Center-Parnassus - San Francisco
Illinois
- Lurie Children's Hospital-Chicago - Chicago
- Children's Memorial Outpatient Center in Lincoln Park - Chicago
Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- Texas Children's Hospital - Houston
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Maryland
- National Institutes of Health Clinical Center - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-07-07 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 1 |
What the registry record for NCT01089101 still lists
NCT01089101 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (109% higher).
The record links to 6 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT01089101 lists 17 locations in 12 states (California, Illinois, Texas).
Frequently Asked Questions
What is clinical trial NCT01089101 about?
NCT01089101 is a clinical study titled "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma". This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocki...
What is the current status of trial NCT01089101?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2010-07-07. Estimated completion is 2027-03-18.
What conditions does trial NCT01089101 study?
This clinical trial studies the following conditions: Low Grade Glioma, Recurrent Visual Pathway Glioma, Refractory Visual Pathway Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1.
What interventions are being tested in trial NCT01089101?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT01089101?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01089101 being conducted?
This trial has 17 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01089101's enrollment target sits among peer trials
217 2nd of 23 the highest of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
-
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
RECRUITING · Phase 1
-
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI